Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 688 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
13 Results
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
- Leukemia & Hematologic Cancers
- Pediatric Cancers
- Gender:All Genders
- Age:21 years and younger
The Impact of Phosphate Metabolism on Healthy Aging
- Kidney & Urinary Tract
- Gender:All Genders
- Age:13 years and older
Study to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta
- Orthopaedics, Muscle & Bone
- Gender:All Genders
- Age:5 years - 25 years
Setrusumab vs bisphosphonates in children from 2 to < 7 years old with osteogenesis imperfecta (OI)
- Genetics
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- Leukemia & Hematologic Cancers
Testing Atezolizumab with Selinexor in People ≥ 12 Years Old with Alveolar Soft Part Sarcoma, The AXIOM Trial
- Sarcoma Cancers
Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy
- Lung Cancer
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
- Gynecological Cancers
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML
- Leukemia & Hematologic Cancers
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
- Brain & Other Nervous System Cancers
1-10 of 13 Results